Light-adjustable IOLs provide stable outcomes

Article

Light-adjustable intraocular lenses (IOLs) provide near-emmetropic refractive outcomes and good uncorrected distance visual acuity that remains stable over time, according to a recent study.

Light-adjustable intraocular lenses (IOLs) provide near-emmetropic refractive outcomes and good uncorrected distance visual acuity that remains stable over time, according to a study published in the Journal of Cataract and Refractive Surgery.

Researchers at University Hospital Virgen de la Arrixaca, Murcia, Spain, performed a prospective non-randomized clinical trial of 53 eyes in 49 patients that had been implanted with a light-adjustable IOL. The researchers used spatial intensity profiles to correct refractive errors in the eyes, and estimated the effective changes in the IOLs' refraction after every treatment by subtracting those in the whole eye and the cornea.

After every light treatment and at 3-, 6- and 12-months, the researchers measured the refractive changes in the whole eye, refractive changes in the IOL, manifest refraction and visual acuity.

A maximum change in spherical power of the light-adjustable IOL of between −1.98 D and +2.30 D was induced by the combination of 2 light adjustments. In astigmatism the maximum change was up to −2.68 D. Axis errors were below 9 degrees. A small myopic shift of +0.01 to +0.57 D was produced by the 2 'lock-in' procedures.

To read an abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.